Country: Bandaríkin
Tungumál: enska
Heimild: NLM (National Library of Medicine)
CLOPIDOGREL BISULFATE (UNII: 08I79HTP27) (CLOPIDOGREL - UNII:A74586SNO7)
St Marys Medical Park Pharmacy
CLOPIDOGREL BISULFATE
CLOPIDOGREL 75 mg
PRESCRIPTION DRUG
Abbreviated New Drug Application
CLOPIDOGREL - CLOPIDOGREL TABLET, FILM COATED ST MARYS MEDICAL PARK PHARMACY ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CLOPIDOGREL TABLETS USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CLOPIDOGREL TABLETS USP. CLOPIDOGREL TABLETS USP FOR ORAL USE INITIAL U.S. APPROVAL: 1997 WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ EFFECTIVENESS OF CLOPIDOGREL DEPENDS ON ACTIVATION TO AN ACTIVE METABOLITE BY THE CYTOCHROME P450 (CYP) SYSTEM, PRINCIPALLY CYP2C19. (5.1) POOR METABOLIZERS TREATED WITH CLOPIDOGREL AT RECOMMENDED DOSES EXHIBIT HIGHER CARDIOVASCULAR EVENT RATES FOLLOWING ACUTE CORONARY SYNDROME (ACS) OR PERCUTANEOUS CORONARY INTERVENTION (PCI) THAN PATIENTS WITH NORMAL CYP2C19 FUNCTION. (12.5) TESTS ARE AVAILABLE TO IDENTIFY A PATIENT'S CYP2C19 GENOTYPE AND CAN BE USED AS AN AID IN DETERMINING THERAPEUTIC STRATEGY. (12.5) CONSIDER ALTERNATIVE TREATMENT OR TREATMENT STRATEGIES IN PATIENTS IDENTIFIED AS CYP2C19 POOR METABOLIZERS. (2.3, 5.1) RECENT MAJOR CHANGES Warnings and Precautions (5.6) 12/2013 INDICATIONS AND USAGE Clopidogrel tablets USP are a P2Y platelet inhibitor indicated for: Acute coronary syndrome For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel tablets USP have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. (1.1) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets USP have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary PCI is unknown. (1.1) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets USP have Lestu allt skjalið